MAP2K7 and melanoma: Our results suggest that KDR may be a predictive marker of vemurafenib and or MEK inhibitor response and the combination of cediranib and BRAF or MEK inhibitors are an actionable combinatorial regimen for melanoma patients with BRAF mutations.